Another vaccine on the way to approval: A week after recommending approving the Pfizer vaccine by Pfizer – which gave the green light for the start of a global vaccination campaign to defeat the virus – the US Food and Drug Administration (FDA) has convened again, and tonight (Friday) recommended approving the vaccine as well. Developed by the “Modern” company for the corona virus.
For more updates and to send your stories – visit the news Facebook page
According to U.S. reports, 20 of the committee members voted in favor, with only 1 abstaining. This is a significant improvement over Pfizer’s vaccine vote last week, in which 17 committee members voted in favor of the vaccine, 4 opposed and one abstained. Now that the committee has decided to recommend About the vaccine approval, the FDA is expected to announce an official approval over the coming weekend.
As mentioned, the US welcomes the commission’s recommendation as part of the fight against the corona virus, and hopes to start moving Modern vaccines as early as next Monday. Now that two different vaccines are expected to be approved by the FDA in parallel, Washington hopes that by the end of the civil year 20 million people will be vaccinated.
Before the decision was made, Dr. Tal Zacks, the medical director of Moderna, presented the innovative and promising development of the RNA vaccine that the company had developed against the virus, in just a few months. “An increase in the severity of the expected systemic symptoms, such as headaches and muscle aches, after the second dose of vaccine. They go away on their own and we did not recognize that they pose a significant danger.”
This is said against the background of various cases of side effects among the first vaccinated with the “Pfizer” vaccine that are reported in the media. During the injection of the vaccine in the state of Alaska in the United States, two injectors developed symptoms of acute allergy – and both recovered. In the United States today allergy sufferers are advised to be careful and get the vaccine where, if an allergic reaction develops, it can be treated quickly and effectively.
Thirty-six days after the modern vaccine trials received the first injection, all subjects of all ages showed high levels of antibodies to the virus. The vaccine was also found to prevent disease in all age groups over 18 – and also in risk groups. No abnormal side effects were reported and in all cases passed in less than a week. The “Modern” vaccine is also considered simpler to transport and inject than the Pfizer vaccine.
“Modern” will supply Israel with 6 million vaccine doses
Two weeks ago, the Ministry of Health signed an agreement with Moderna to triple the amount of vaccines the company will supply to Israel in 2021 – from two million vaccines to six million vaccines, which will be enough to vaccinate three million citizens (each vaccinated person receives two vaccine doses). The Israeli vaccination campaign is expected to begin this coming Monday, December 21, with the vaccines of the Pfizer company, whose 700,000 doses have already arrived in Israel.
The first to be vaccinated in Israel will be medical staff who will receive the vaccines as early as this coming Sunday – and from Monday, they will also be able to vaccinate people aged 60 and over and at-risk populations at the HMOs, who have already begun receiving the first summons to get vaccinated. Apparently already at the end of this month or the beginning of next month, the whole population will be able to get the vaccine.
The complete guide to the great vaccination campaign